Drug Discovery
By
Can This AI-Driven Biotech Duo Cut Biologic Development Timelines by 40%? Axio and Likarda Bet on It
Key Highlights • AI-driven protein production from Axio BioPharma integrates with Likarda’s Core-Shell Spherification® (CSS®) delivery platform to…
Can MIT and Recursion’s New AI Model Boltz-2 Slash Drug Discovery Time by 1000x and Outperform AlphaFold3?
Key Takeaways• Boltz-2 delivers AI-driven binding affinity predictions 1000x faster than traditional free energy methods—dramatically accelerating virtual screening…
Is Optic and Mechanica’s AI Venture Model the Future of Biotech Creation? Strategic Expansion Unifies Drug Discovery and Business Insight at Scale
Key Highlights Strategic Collaboration to Power AI-Led Biotech GrowthOptic, Inc., a pioneer in AI platforms for biopharma, has…
Is the OBI Pharma–TegMine Therapeutics ADC Deal the Next Leap in Precision Oncology Using Glycan-Based Technologies?
Key Highlights 1. Powering the Next-Gen ADC Revolution: OBI’s GlycOBI® Meets TegMine’s TegMiner™The collaboration between Taiwan-based OBI Pharma…
Can Syntis Bio’s $38M Series A Transform Oral Biologics for Obesity and Rare Diseases?
Key Highlights Funding to Advance Novel Oral TherapiesBoston-based Syntis Bio announced the close of its $38 million financing…
Can Catalio Capital’s $400 Million AI-Driven Life Sciences Fund Ignite a New Era of Biomedical Innovation Despite a Slow VC Market?
Key Takeaways Resilience in a Cooling VC ClimateCatalio Capital Management has successfully closed its fourth Nexus Fund at…
